WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Bristol-Myers Squibb

Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

www.bms.com.

Bristol-Myers Squibb RSS Channel

Filters
List of articles in category Bristol-Myers Squibb
Title Published Date
Onglyza® (saxagliptin) achieves primary safety endpoint in SAVOR cardiovascular outcomes trial 02 September 2013
Bristol-Myers Squibb and Samsung BioLogics announce biopharmaceutical manufacturing relationship 29 July 2013
Bristol-Myers Squibb reports second quarter 2013 financial results 25 July 2013
Bristol-Myers Squibb and Simcere enter partnership to co-develop and co-commercialize Orencia® SC (abatacept) in China 14 June 2013
FDA grants Priority Review to Bristol-Myers Squibb and AstraZeneca's Metreleptin 04 June 2013
Bristol-Myers Squibb and Pfizer announce publication of ARISTOTLE subanalysis in Circulation 06 May 2013
Bristol-Myers Squibb reports first quarter 2013 financial results 25 April 2013
Bristol-Myers Squibb enters a collaboration agreement with Reckitt Benckiser Group plc 12 February 2013
Bristol-Myers Squibb reports fourth quarter financial results 24 January 2013
FDA approves ELIQUIS® (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation 02 January 2013
Bristol-Myers Squibb Foundation's Together on Diabetes™ marks World Diabetes Day 14 November 2012
Portola, Bristol-Myers Squibb and Pfizer sign clinical collaboration agreement to study ELIQUIS® and Portola's universal Factor Xa inhibitor antidote PRT4445 01 November 2012
Bristol-Myers Squibb reports third quarter 2012 financial results 24 October 2012
YERVOY® (ipilimumab) awarded prestigious Prix Galien USA 2012 for best biotechnology product 17 October 2012
ELIQUIS® (apixaban) demonstrates consistent reductions in stroke and systemic embolism, major bleeding and mortality 02 October 2012
Vanderbilt University and Bristol-Myers Squibb sign collaboration agreement to develop novel treatments for parkinson's Disease 23 September 2012
Bristol-Myers Squibb and AstraZeneca complete expansion of diabetes alliance 09 August 2012
Bristol-Myers Squibb Foundation awards $1.6 million in grants 06 August 2012
Bristol-Myers Squibb and AstraZeneca expand diabetes alliance 01 July 2012
Bristol-Myers Squibb and Emory University announce partnership 20 June 2012
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
  • CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma

Research & Development

  • Candidate found to inhibit malignant melanoma growth
  • A nasal spray protects against coronavirus infection - Effective also against recent immune-evasive variants
  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA approves first over-the-counter naloxone nasal spray
  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  1. You are here:  
  2. Home
  3. Bristol-Myers Squibb

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.